MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318273 | Name: Milnacipran HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Milnacipran is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia. It is not approved for the clinical treatment of major depressive disorder in the USA, but it is in other countries.

Chemical Structure

Milnacipran HCl
Milnacipran HCl
CAS#101152-94-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 318273

Name: Milnacipran HCl

CAS#: 101152-94-7 (HCl)

Chemical Formula: C15H23ClN2O

Exact Mass: 246.1732

Molecular Weight: 282.81

Elemental Analysis: C, 63.70; H, 8.20; Cl, 12.53; N, 9.91; O, 5.66

Price and Availability

Size Price Availability Quantity
50mg USD 250.00 2 weeks
500mg USD 950.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
101152-94-7 (HCl) 92623-85-3 (free base)
Synonym
Milnacipran, Levomilnacipran, F-2207, Ixel, Savella, Dalcipran, Toledomin
IUPAC/Chemical Name
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride
InChi Key
XNCDYJFPRPDERF-PBCQUBLHSA-N
InChi Code
InChI=1S/C15H22N2O.ClH/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12;/h5-9,13H,3-4,10-11,16H2,1-2H3;1H/t13-,15+;/m1./s1
SMILES Code
O=C([C@@]1(C2=CC=CC=C2)[C@@H](CN)C1)N(CC)CC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Milnacipran hydrochloride is a serotonin-norepinephrine reuptake inhibitor.
In vitro activity:
To determine the in vitro effect of milnacipran on four recombinant LGIC receptors, nicotinic acetylcholine, N-methyl-D-aspartate, gamma-amino butyric acid (GABA) and 5-hydroxytryptamine3A receptors. At high concentrations, milnacipran can inhibit certain LGICs (ligand-gated ion-channel). Reference: Psychopharmacology (Berl). 2004 Sep;175(2):241-6. https://pubmed.ncbi.nlm.nih.gov/14997275/
In vivo activity:
The fifth left lumbar nerve of male C57BL6 mice was tightly ligated. Withdrawal threshold to tactile stimulation and withdrawal latency to heat stimulation in the injured or contralateral paw was tested by using von Frey filaments and radiant heat, respectively. Milnacipran was administered either orally (7.5-120 mg/kg), intrathecally, intracerebroventricularly, or locally (210 ng-21 microg). Both systemic, intrathecal and intracerebroventricular milnacipran increased withdrawal threshold and withdrawal latency in nerve-ligated mice whereas local injection had no effect. Reference: Anesth Analg. 2008 Apr;106(4):1309-15. https://pubmed.ncbi.nlm.nih.gov/18349211/
Solvent mg/mL mM
Solubility
DMF 20.0 70.72
DMSO 41.6 146.99
Ethanol 45.0 159.12
PBS (pH 7.2) 10.0 35.36
Water 61.8 218.38
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 282.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos. 2009 Oct;37(10):2045-54. doi: 10.1124/dmd.109.028274. Epub 2009 Jul 16. PMID: 19608694. 2. Ueta K, Suzuki T, Uchida I, Mashimo T. In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran. Psychopharmacology (Berl). 2004 Sep;175(2):241-6. doi: 10.1007/s00213-004-1808-8. Epub 2004 Mar 2. PMID: 14997275. 3. Suzuki T, Ueta K, Tamagaki S, Mashimo T. Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth Analg. 2008 Apr;106(4):1309-15, table of contents. doi: 10.1213/ane.0b013e318167889a. PMID: 18349211. 4. Mochizuki D, Tsujita R, Yamada S, Kawasaki K, Otsuka Y, Hashimoto S, Hattori T, Kitamura Y, Miki N. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl). 2002 Jul;162(3):323-32. doi: 10.1007/s00213-002-1111-5. Epub 2002 Jun 12. PMID: 12122491.
In vitro protocol:
1. Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos. 2009 Oct;37(10):2045-54. doi: 10.1124/dmd.109.028274. Epub 2009 Jul 16. PMID: 19608694. 2. Ueta K, Suzuki T, Uchida I, Mashimo T. In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran. Psychopharmacology (Berl). 2004 Sep;175(2):241-6. doi: 10.1007/s00213-004-1808-8. Epub 2004 Mar 2. PMID: 14997275.
In vivo protocol:
1. Suzuki T, Ueta K, Tamagaki S, Mashimo T. Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth Analg. 2008 Apr;106(4):1309-15, table of contents. doi: 10.1213/ane.0b013e318167889a. PMID: 18349211. 2. Mochizuki D, Tsujita R, Yamada S, Kawasaki K, Otsuka Y, Hashimoto S, Hattori T, Kitamura Y, Miki N. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl). 2002 Jul;162(3):323-32. doi: 10.1007/s00213-002-1111-5. Epub 2002 Jun 12. PMID: 12122491.
1: Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2015 Oct 20;10:CD008244. doi: 10.1002/14651858.CD008244.pub3. Review. PubMed PMID: 26482422. 2: Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. Cochrane Database Syst Rev. 2015 Jul 6;7:CD011789. doi: 10.1002/14651858.CD011789. Review. PubMed PMID: 26148202. 3: Bernstein CD, Albrecht KL, Marcus DA. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium. Expert Opin Pharmacother. 2013 May;14(7):905-16. doi: 10.1517/14656566.2013.779670. Epub 2013 Mar 19. Review. PubMed PMID: 23506481. 4: Derry S, Gill D, Phillips T, Moore RA. Milnacipran for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012 Mar 14;3:CD008244. doi: 10.1002/14651858.CD008244.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;10:CD008244. PubMed PMID: 22419330; PubMed Central PMCID: PMC4164830. 5: Häuser W, Petzke F, Üçeyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford). 2011 Mar;50(3):532-43. doi: 10.1093/rheumatology/keq354. Epub 2010 Nov 14. Review. PubMed PMID: 21078630. 6: Kyle JA, Dugan BD, Testerman KK. Milnacipran for treatment of fibromyalgia. Ann Pharmacother. 2010 Sep;44(9):1422-9. doi: 10.1345/aph.1P218. Epub 2010 Aug 17. Review. PubMed PMID: 20716692. 7: Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010 Jun;11(6):505-21. doi: 10.1016/j.jpain.2010.01.002. Epub 2010 Apr 24. Review. PubMed PMID: 20418173. 8: Higuchi H. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Apr;30(2):71-6. Review. Japanese. PubMed PMID: 20491280. 9: Pae CU, Marks DM, Shah M, Han C, Ham BJ, Patkar AA, Masand PS. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009 Nov-Dec;32(6):355-63. doi: 10.1097/WNF.0b013e3181ac155b. Review. PubMed PMID: 19620845. 10: Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006529. doi: 10.1002/14651858.CD006529.pub2. Review. PubMed PMID: 19588396; PubMed Central PMCID: PMC4164845. 11: Owen RT. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc). 2008 Sep;44(9):653-60. doi: 10.1358/dot.2008.44.9.1256003. Review. PubMed PMID: 19137120. 12: Bisserbe JC. Clinical utility of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol. 2002 Jun;17 Suppl 1:S43-50. Review. PubMed PMID: 12369610. 13: Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol. 2002 Jun;17 Suppl 1:S25-35. Review. PubMed PMID: 12369608. 14: Spencer CM, Wilde MI. Milnacipran. A review of its use in depression. Drugs. 1998 Sep;56(3):405-27. Review. PubMed PMID: 9777315. 15: Montgomery SA, Prost JF, Solles A, Briley M. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:47-51. Review. PubMed PMID: 8923127. 16: Kasper S, Pletan Y, Solles A, Tournoux A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:35-9. Review. PubMed PMID: 8923125. 17: Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:15-27. Review. PubMed PMID: 8923123. 18: Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA; Multiple Meta-Analyses of New-Generation Antidepressants (MANGA) Study Group. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis. CNS Drugs. 2008;22(7):587-602. Review. PubMed PMID: 18547127. 19: Leo RJ, Brooks VL. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs. 2006 Jul;7(7):637-42. Review. PubMed PMID: 16869117. 20: Preskorn SH. Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor. J Psychiatr Pract. 2004 Mar;10(2):119-26. Review. PubMed PMID: 15330407.